Valuation Madrigal Pharmaceuticals, Inc. Deutsche Boerse AG
Stocks
YDO1
US5588681057
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
20:00:34 01/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 448.00 EUR | +0.83% |
|
-1.09% | -10.14% |
| 09-24 | Analyst recommendations: Dropbox, Etsy, Meta Platforms, Okta, Rollins… |  |
| 09-23 | Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target | MT |
Company Valuation: Madrigal Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,449 | 5,179 | 4,568 | 6,730 | 13,226 | 11,644 | - | - |
| Change | - | 257.45% | -11.79% | 47.33% | 96.52% | -11.96% | - | - |
| Enterprise Value (EV) 1 | 1,179 | 4,869 | 4,051 | 5,922 | 12,584 | 11,119 | 10,700 | 9,593 |
| Change | - | 313.04% | -16.81% | 46.21% | 112.48% | -11.64% | -3.77% | -10.35% |
| P/E | -5.79x | -16.8x | -11.6x | -14.1x | -45.3x | -80.1x | 92.9x | 23.5x |
| PBR | 7.15x | 26.6x | 11.3x | 9x | 22.1x | 25.9x | 14.2x | 7.01x |
| PEG | - | -0.9x | -0.7x | -1.48x | 1.1x | 1.6x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 37.4x | 13.8x | 7.62x | 5.47x | 4.04x |
| EV / Revenue | - | - | - | 32.9x | 13.1x | 7.28x | 5.03x | 3.33x |
| EV / EBITDA | -4.87x | -16.6x | -10.7x | -11.9x | -42.1x | -62.4x | 78.9x | 16x |
| EV / EBIT | -4.86x | -16.6x | -10.6x | -11.9x | -41.9x | -59.5x | 64.1x | 14.1x |
| EV / FCF | -4.87x | -16.6x | -12.4x | -13x | -66.2x | -55.5x | 39.4x | 12x |
| FCF Yield | -20.6% | -6.01% | -8.04% | -7.72% | -1.51% | -1.8% | 2.54% | 8.35% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.63 | -17.23 | -19.99 | -21.9 | -12.85 | -6.289 | 5.425 | 21.41 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 180.1 | 958.4 | 1,527 | 2,128 | 2,879 |
| EBITDA 1 | -242.1 | -293.1 | -380 | -496.8 | -298.6 | -178.2 | 135.7 | 599.7 |
| EBIT 1 | -242.5 | -293.6 | -380.5 | -497.9 | -300.1 | -186.8 | 166.9 | 681.8 |
| Net income 1 | -241.8 | -295.4 | -373.6 | -465.9 | -288.3 | -183 | 178.9 | 667.9 |
| Net Debt 1 | -269.9 | -309.5 | -517.5 | -807.7 | -642 | -524.5 | -943.2 | -2,051 |
| Reference price 2 | 84.74 | 290.25 | 231.38 | 308.57 | 582.34 | 503.96 | 503.96 | 503.96 |
| Nbr of stocks (in thousands) | 17,097 | 17,842 | 19,743 | 21,810 | 22,711 | 23,104 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 28/02/24 | 26/02/25 | 19/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.77x | 15.61x | 1.37% | 74.46B | |
| 31.25x | 9.01x | 28.06x | 0.04% | 60.14B | |
| 33.64x | 6.03x | 18.07x | 0.97% | 48.15B | |
| 34.63x | 3.34x | 14.4x | -.--% | 44.25B | |
| -21.16x | 229.18x | -22.81x | -.--% | 43.99B | |
| 47.94x | 5.54x | 30.43x | -.--% | 41.61B | |
| 26.89x | 7.76x | 19.96x | 0.42% | 29.97B | |
| 33.91x | 7.26x | 18.84x | -.--% | 29.31B | |
| -70.02x | 13.44x | -68.51x | -.--% | 24.93B | |
| Average | 15.42x | 32.15x | 6.01x | 0.31% | 44.09B | |
| Weighted average by Cap. | 19.58x | 31.88x | 10.24x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MDGL Stock
- YDO1 Stock
- Valuation Madrigal Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
